GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genflow Biosciences PLC (OTCPK:GENFF) » Definitions » Insider Ownership

GENFF (Genflow Biosciences) Insider Ownership : 0.00 % (As of Dec. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Genflow Biosciences Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genflow Biosciences's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genflow Biosciences's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genflow Biosciences's Float Percentage Of Total Shares Outstanding is 0.00%.


Genflow Biosciences Insider Ownership Historical Data

The historical data trend for Genflow Biosciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genflow Biosciences Insider Ownership Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Insider Ownership
- - -

Genflow Biosciences Quarterly Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Insider Ownership Get a 7-Day Free Trial - - - - -

Genflow Biosciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Genflow Biosciences Business Description

Traded in Other Exchanges
Address
6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.